Table 2.
Treatment outcomes for MDR-TB and serial changes of positron emission tomography/computed tomography (PET/CT) parameters.
| Patient No. | Drug Resistance | Treatment Regimens | Outcome | PET/CT | Highest SUVmax | Mean SUVavg | TMLV (cm3) | TLG (cm3) |
|---|---|---|---|---|---|---|---|---|
| 1 | INH, RFP, EMB, PAS | PZA, KM, MFX, PTO, CS | Success | Baseline | 7.8 | 4.1 | 31.4 | 129.8 |
| 6 mo | 4.8 | 3.1 | 2.0 | 6.1 | ||||
| 12 mo | 2.3 | NA | NA | NA | ||||
| 2 | INH, RFP, FQ, EMB, PAS | KM, PTO, CS, LZD, BDQ, CFZ | Failure | Baseline | 6.6 | 3.3 | 92.3 | 307.3 |
| 6 mo | 3.4 | 2.9 | 0.4 | 1.3 | ||||
| 12 mo | NV | NA | NA | NA | ||||
| 3 | INH, RFP, FQ, EMB | EMB, KM, PTO, CS, LZD, BDQ | Success | Baseline | 5.4 | 3.1 | 11.0 | 34.3 |
| 6 mo | 4.6 | 3.0 | 2.0 | 5.9 | ||||
| 12 mo | 2.3 | NA | NA | NA | ||||
| 4 | INH, RFP, EMB, PAS | PZA, KM, MFX, PTO, CS | Success | Baseline | 4.6 | 3.0 | 4.6 | 14.1 |
| 6 mo | 5.6 | 3.6 | 6.3 | 22.7 | ||||
| 12 mo | 4.7 | 3.3 | 3.7 | 12.2 |
Abbreviations: MDR-TB, multidrug-resistant tuberculosis; AFB, acid-fast bacilli; INH, isoniazid; EMB, ethambutol; RFP, rifampin; FQ, fluoroquinolone; PZA, pyrazinamide; KM, kanamycin; MFX, moxifloxacin; PTO, prothionamide; CS, cycloserine; PAS, para-aminosalicylic acid; LZD, linezolid; BDQ, bedaquiline; CFZ, clofazimine; PET/CT, positron emission tomography/computed tomography; SUV, standardized uptake value; TMLV, total metabolic lung volume; TLG, total lung glycolysis; NA, not applicable; NV, non-visualized; mo: month.